Navigation Links
Response Genetics Reports Second Quarter 2007 Financial Results
Date:8/19/2007

ash equivalents at June 30, 2007 were $19.4 million compared to $4.9 million at December 31, 2006. On June 8, Response Genetics completed its initial public offering of 3,000,000 shares of its common stock at a price of $7.00 per share.

Corporate Highlights

Completion of Initial Public Offering

On June 5, Response Genetics announced its initial public offering of 3,000,000 shares of its common stock at a price of $7.00 per share. Shares of Response Genetics' stock began trading on the NASDAQ under the symbol "RGDX" that day. Maxim Group LLC acted as lead underwriter and representative of the underwriters of the offering, and Caris & Company acted as co-manager.

Opening of European Laboratory in Edinburgh, Scotland

On July 2, the Company announced the opening of its first European laboratory in Edinburgh, Scotland. This is the first in a series of strategically placed global laboratories that the Company plans to open to support the pharmaceutical industry's need for genetic analysis of their global clinical trial specimens. The Edinburgh laboratory is now open, fully equipped and able to analyze clinical trial specimens.

Data Publication in Journal of Clinical Oncology

On July 9, positive Phase III clinical data results were published in the July 1 issue of the Journal of Clinical Oncology, suggesting that low expression of the biomarker Excision-Repair Cross-Complementing 1 (ERCC-1) in patient biopsies with advanced non-small cell lung cancer (NSCLC) predicts for sensitivity to cisplatin-based chemotherapy. ERCC-1 is an enzyme involved in repair of DNA strand breaks such as those caused by cisplatin. The analysis of ERCC-1 levels in this study was conducted by Response Genetics using its RGI-1 technology.

This was the first prospective study using a biomarker to predict chemotherapy response in lung cancer. These findings support the use of measurement of ERCC-1 for individualizing therapies for lung cancer patients.<
'/>"/>

SOURCE Response Genetics, Inc.

Copyright©2007 PR Newswire.

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Performance of Ad-A-Gene Cyclic AMP Response Element-Nitroreductase (CRE-NTR): an adenoviral vector gene delivery system
2. FLIPR Calcium 3 Assay Kit - An Optimal No-Wash Fluorescence Calcium Indicator Reagent for Non-Optimal Calcium Responses
3. IT critical in pandemic response, but many are not paying attention
4. Quick response manufacturing and biotech
5. Wisconsin court affirms damages in Innogenetics, Abbott patent case
6. Third Wave licenses Innogenetics tech to settle lawsuit
7. Symposium examines the effect of race on genetics and disease
8. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
9. Sonic Foundry reports GAAP loss as Q2 revenues rise
10. Fiserv reports $113.5 million in Q1 profit
11. Third Wave reports net loss of $18.9M for 2006
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... September 02, 2014 Opertech Bio, ... highly efficient, cost effective approach to sensory evaluation, ... 8,820,265 by the U.S. Patent and Trademark Office, ... , “Opertech’s taste evaluation technology called ... automated high throughput system for rapid characterization of ...
(Date:9/2/2014)... , Sept. 2, 2014  Xencor, Inc. (NASDAQ: ... developing engineered monoclonal antibodies for the treatment of ... today announced the appointment of Debra Zack ... the appointment of Lloyd Rowland , senior ... "Debra,s expertise in biologics clinical ...
(Date:9/2/2014)... ROCKVILLE, Md. , Sept. 2, 2014 /PRNewswire/ ... of novel anti-infective biologic and drug candidates targeting ... announced today positive results from its final preclinical ... Drug Administration (FDA) guidance, this bridging study was ... product candidate designed to prevent the devastating effects ...
(Date:9/2/2014)... Mount, NC (PRWEB) September 02, 2014 ... establishment of its 11th clinical research site: PMG Research ... assumed ownership and operation of the clinical research department ... further expanding PMG’s presence in eastern North Carolina. This ... patients. For the patients in Rocky Mount and the ...
Breaking Biology Technology:Opertech Bio Receives U.S. Patent for High-Throughput Taste Evaluation Technology 2Xencor Appoints Debra Zack, M.D., Ph.D., Vice President, Clinical Development and Lloyd Rowland, Senior Vice President, Chief Compliance Officer and General Counsel 2Xencor Appoints Debra Zack, M.D., Ph.D., Vice President, Clinical Development and Lloyd Rowland, Senior Vice President, Chief Compliance Officer and General Counsel 3Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 2Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 3Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 4Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 5PMG Research Announces the Formation of its Eleventh Site 2PMG Research Announces the Formation of its Eleventh Site 3
... 25 BN,ImmunoTherapeutics, Inc. announced today that the ... licensed from the National Institutes of,Health (NIH) is ... the,excellent safety and efficacy results previously reported, will ... on February 26-28, 2009 in,Orlando, Florida. , ...
... 25 /PRNewswire-Asia-FirstCall/ -- 3SBio Inc. (Nasdaq:, SSRX ... researching,developing, manufacturing and marketing biopharmaceutical products, today,announced that ... quarter and,full year ended December 31, 2008 after ... , Following the earnings ...
... Cerimon Pharmaceuticals, Inc., announced today the Company has enrolled ... patch Phase III program. The program consists of ... Cerimon,s diclofenac patch. The studies will assess the ... placebo for the treatment of acute pain caused by ...
Cached Biology Technology:BN ImmunoTherapeutics Reports Further Data on PROSTVAC(TM) 2BN ImmunoTherapeutics Reports Further Data on PROSTVAC(TM) 33SBio Inc. to Report 2008 Fourth Quarter and Full Year Earnings on March 11, 2009 2Cerimon Pharmaceuticals Initiates Phase III Clinical Studies to Evaluate Its Topical Diclofenac Sodium Patch for Mild-to-Moderate Pain 2
(Date:9/2/2014)... non-indigenous women in Queensland, Australia, is closing, however indigenous ... preventable causes, find researchers in a new study published ... of Obstetrics and Gynaecology ( BJOG ). , ... Data Collection and looked at 881,211 singleton births from ... in stillbirth rates over time among indigenous (Australian Aboriginal ...
(Date:9/2/2014)... blogs: Earthquake rupture through a U.S. suburb , ... California Davis in the hours and days after the ... understand why the earthquake caused so much damage in ... Earth blog, hosted by the American Geophysical Union. ... Rovers: The Next Places to Direct Our Curiosity ...
(Date:9/2/2014)... 3, The Field Museum will present the prestigious Parker/Gentry ... his commitment to biodiversity conservation awareness. The Parker/Gentry Award ... outstanding individual, team or organization whose efforts have had ... heritage and whose actions can serve as a model ... Mongabay.com, an environmental science and conservation news website that ...
Breaking Biology News(10 mins):Stillbirth gap closing between indigenous and non-indigenous women, shows Australian study 2Stillbirth gap closing between indigenous and non-indigenous women, shows Australian study 3This week From AGU: California earthquake, future Mars rovers, models underestimate ozone 2
... and smoke forecasting models are useful tools to help ... in areas at risk from forest fire smoke, according ... Brauer shares his insight into the health impacts ... them today at the American Association for the Advancement ...
... This press release is available in French . ... are lots of new ideas out there for giving you extra ... good ideas may never make it to market. Researchers ... a way to enrich milk with docosahexaeonic acid (DHA)an essential nutrient ...
... An international team from the Nippon Foundation-University of British ... of life in the world,s oceans, allowing scientists and ... the state of life in the oceans of ... factors impacting our oceans climate change, human activity ...
Cached Biology News:As climate change increases forest fires, smoke forecasting could help protect public health 2Window into world's future oceans unveiled by NF-UBC Nereus team 2Window into world's future oceans unveiled by NF-UBC Nereus team 3
... Neutralizing synthetic peptide for OPA1-01009, OPEP-01009 is a 16 ... from human DNA fragmentation factor (DFF). The sequence of ... - P - K - S - V - K ... - S - P - R - K(18). ...
... intended for laboratory research use only. ... buffered formalin and embedded in paraffin. ... certified pathologists. Tissue cores were removed ... a new recipient paraffin block, in an ...
... High Throughput Processing of Microarrays Using the ... Frame multiple slide plate is designed to ... corresponding multi-well incubation chambers in a microplate ... The footprint dimensions meet the standards recommended ...
fully automated system for the processing of microarrays on microscope slides...
Biology Products: